Literature DB >> 6140273

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

M Ishibashi, T Yamaji.   

Abstract

To determine the mechanism and the site of action of catecholamines as well as hormones including thyrotropin-releasing hormone (TRH)1 and somatostatin on pituitary hormone release in patients with acromegaly and in normal subjects, the effects of these substances on growth hormone (GH) and prolactin (PRL) secretion from adenomatous and nonadenomatous human pituitary cells in culture were examined. When dopamine (0.01-0.1 microM) or bromocriptine (0.01-0.1 microM) was added to the culture media, a significant inhibition of GH and PRL secretion from adenoma cells from acromegalic patients was observed. This inhibition was blocked by D2 receptor blockade with metoclopramide or sulpiride, but not by D1 receptor blockade. Similarly, dopamine suppressed GH and PRL release by nonadenomatous pituitary cells in a dose-dependent manner, which was again blocked by D2 receptor blockade. The minimum effective concentration of dopamine required for a significant inhibition of PRL secretion (0.01 microM) was lower than that for GH release (0.1 microM). Norepinephrine, likewise, caused a suppression of PRL secretion from adenomatous and nonadenomatous pituitary cells. This effect was blocked by sulpiride, phentolamine, however, was ineffective. When TRH was added to the media, both GH and PRL secretion were enhanced in adenoma cells, while only the stimulation of PRL release was observed in nonadenomatous pituitary cells. Coincubation of TRH and dopamine resulted in variable effects on GH and PRL secretion. Somatostatin consistently lowered GH and PRL secretion in both adenomatous and nonadenomatous pituitary cells and completely blocked the TRH-induced stimulation of GH and PRL secretion from adenoma cells. Opioid peptides (1 microM) failed to affect hormone release. These results suggest that no qualitative difference in GH and PRL responses to dopaminergic agonists or to somatostatin exists between adenoma cells of acromegalic patients and normal pituitary cells, and that the direct effect of catecholamines on GH and PRL secretion from human pituitary cells is mediated mainly through dopamine receptor activation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6140273      PMCID: PMC424971          DOI: 10.1172/JCI111208

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Stimulation of human-growth-hormone secretion by L-dopa.

Authors:  A E Boyd; H E Lebovitz; J B Pfeiffer
Journal:  N Engl J Med       Date:  1970-12-24       Impact factor: 91.245

2.  Characterization of growth hormone of different molecular weights in rat, dog and human pituitaries.

Authors:  L A Frohman; L Burek; M A Stachura
Journal:  Endocrinology       Date:  1972-07       Impact factor: 4.736

3.  Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism.

Authors:  M Irie; T Tsushima
Journal:  J Clin Endocrinol Metab       Date:  1972-07       Impact factor: 5.958

4.  Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

5.  Dopamine affects basal and augmented pituitary hormone secretion.

Authors:  W F Leebaw; L A Lee; P D Woolf
Journal:  J Clin Endocrinol Metab       Date:  1978-09       Impact factor: 5.958

6.  Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system.

Authors:  D Bression; A M Brandi; A Nousbaum; M Le Dafniet; J Racadot; F Peillon
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

7.  Induction of growth hormone and prolactin secretion by luteinizing hormone-releasing hormone and its blockade by bromoergocriptine in acromegalic patients.

Authors:  M Ishibashi; T Yamaji; K Kosaka
Journal:  J Clin Endocrinol Metab       Date:  1978-08       Impact factor: 5.958

8.  Abnormalities in the release of TSH in response to thyrotropin-releasing hormone (TRH) in patients with disorders of the pituitary, hypothalamus and basal ganglia.

Authors:  D S Schalch; D Gonzalez-Barcena; A J Kastin; A V Schally; L A Lee
Journal:  J Clin Endocrinol Metab       Date:  1972-10       Impact factor: 5.958

9.  Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perifusion of normal and adenomatous human pituitary.

Authors:  N F Lawton; A J Evans; R O Weller
Journal:  J Neurol Sci       Date:  1981-02       Impact factor: 3.181

Review 10.  Opiate receptors: enkephalins and endorphins.

Authors:  A Grossman; V Clement-Jones
Journal:  Clin Endocrinol Metab       Date:  1983-03
View more
  8 in total

1.  Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. A double blind placebo-controlled cross-over study.

Authors:  M Andersen; T B Hansen; J Bollerslev; P Bjerre; H D Schrøder; C Hagen
Journal:  J Endocrinol Invest       Date:  1995-12       Impact factor: 4.256

Review 2.  Common tools for pituitary adenomas research: cell lines and primary cells.

Authors:  Ziyan Zhu; Weiwei Cui; Dimin Zhu; Nailin Gao; Yonghong Zhu
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

3.  Hyperphagia in male melanocortin 4 receptor deficient mice promotes growth independently of growth hormone.

Authors:  H Y Tan; F J Steyn; L Huang; M Cowley; J D Veldhuis; C Chen
Journal:  J Physiol       Date:  2016-10-02       Impact factor: 5.182

4.  Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.

Authors:  Willem J van den Brink; Yin C Wong; Berfin Gülave; Piet H van der Graaf; Elizatbeth C M de Lange
Journal:  AAPS J       Date:  2016-10-26       Impact factor: 4.009

5.  The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients.

Authors:  G Gründer; H Wetzel; A Hillert; E Jochum; C Hiemke; O Benkert
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

6.  Hyperpolarization of the membrane potential caused by somatostatin in dissociated human pituitary adenoma cells that secrete growth hormone.

Authors:  N Yamashita; N Shibuya; E Ogata
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

7.  Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D2 receptor activation using multi-biomarker pharmacokinetic/pharmacodynamic modelling.

Authors:  Willem J van den Brink; Dirk-Jan van den Berg; Floor E M Bonsel; Robin Hartman; Yin-Cheong Wong; Piet H van der Graaf; Elizabeth C M de Lange
Journal:  Br J Pharmacol       Date:  2018-08-31       Impact factor: 8.739

Review 8.  A Comparative Update on the Neuroendocrine Regulation of Growth Hormone in Vertebrates.

Authors:  Emilio J Vélez; Suraj Unniappan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-23       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.